Dexamethasone Inhibits the Growth of B‐Lymphoma Cells by Downregulating DOT1L
Cancer Reports · 2024
DOI: 10.1002/cnr2.2150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Yuting Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, College of Basic Medical Sciences, Key Laboratory of Microbial Engineering Under the Educational Committee in Chongqing, …. Hauptthemen laut MEDLINE: Dexamethasone, Histone-Lysine N-Methyltransferase, Cell Proliferation, Receptors, Glucocorticoid. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Dexamethasone (Dex), a synthetic glucocorticoid that acts by binding to the glucocorticoid receptor (GR), has been widely applied to treat leukemia and lymphoma; however, the precise mechanism underlying Dex action is still not well elucidated. DOT1L, a histone H3‐lysine79 (H3K79) methyltransferase, has been linked to multiple cancer types, particularly mixed lineage leukemia (MLL) gene rearranged leukemia, but its contribution to lymphoma is yet to be delineated. Analysis from the TCGA database displayed that DOT1L was highly expressed in lymphoma and leukemia.
Results
We initially demonstrated that DOT1L served as a new target gene controlled by GR, and the downregulation of DOT1L was critical for the killing of B‐lymphoma cells by Dex. Further study revealed that Dex had no impact on the transcriptional activity of the DOT1L promoter, rather it reduced the mRNA level of DOT1L at the posttranscriptional level. In addition, knockdown of DOT1L remarkably inhibited the B‐lymphoma cell growth.
Conclusions
Overall, our findings indicated that DOT1L may serve as a potential drug target and a promising biomarker of Dex sensitivity when it comes to treating B lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, College of Basic Medical Sciences, Key Laboratory of Microbial Engineering Under the Educational Committee in Chongqing, Army Medical University, Chongqing, China.
- Department of Hematology, People's Liberation Army the General Hospital of Western Theater Command, Chengdu, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Army Medical University, Chongqing, China.
ORCID-Profile: Xiancai Rao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Zhang, N., Shang, W., Peng, H., Hu, Z., Yang, Y., Tan, L., Zhang, L., He, F., & Rao, X. (2024). Dexamethasone Inhibits the Growth of B‐Lymphoma Cells by Downregulating DOT1L. Cancer Reports. https://doi.org/10.1002/cnr2.2150
Vancouver
Wang Y, Zhang N, Shang W, Peng H, Hu Z, Yang Y, et al. Dexamethasone Inhibits the Growth of B‐Lymphoma Cells by Downregulating DOT1L. Cancer Reports. 2024. doi:10.1002/cnr2.2150
BibTeX
@article{Wang2024,
author = {Wang, Yuting and Zhang, Nan and Shang, Weilong and Peng, Huagang and Hu, Zhen and Yang, Yi and Tan, Li and Zhang, Li and He, Fengtian and Rao, Xiancai},
title = {Dexamethasone Inhibits the Growth of B‐Lymphoma Cells by Downregulating DOT1L},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2150}
}
EUVIMED